APA (7th ed.) Citation

F, R., CR, T., C, B., L, T., M, R., S, P., . . . M, M. (2025). FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3715. https://doi.org/10.1158/1078-0432.CCR-25-0338

Chicago Style (17th ed.) Citation

F, Rojo, et al. "FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 31, no. 17 (2025): 3715. https://doi.org/10.1158/1078-0432.CCR-25-0338.

MLA (9th ed.) Citation

F, Rojo, et al. "FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 31, no. 17, 2025, p. 3715, https://doi.org/10.1158/1078-0432.CCR-25-0338.